An Exosomal miRNA-based Liquid Biopsy for ICC Detection

Last updated: February 6, 2026
Sponsor: City of Hope Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Liver Cancer

Abdominal Cancer

Biliary Tract Cancer

Treatment

Small RNA sequencing

LUMIC assay

Clinical Study ID

NCT07225452
23228/LUMIC
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Intrahepatic cholangiocarcinoma (ICC) is a malignant liver tumor with poor prognosis and limited curative treatment options. Early and accurate detection remains an unmet clinical need.

The LUMIC study aims to develop a non-invasive liquid biopsy platform based on both exosomal microRNAs (exo-miRNAs) to detect intrahepatic cholangiocarcinoma with high sensitivity and specificity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years

  • Histologically confirmed intrahepatic cholangiocarcinoma

  • Availability of pre-treatment plasma sample

  • Informed consent provided

Exclusion

Exclusion Criteria:

  • Extrahepatic cholangiocarcinoma

  • History of other malignancy within 5 years

  • Active infection, autoimmune disease, or pregnancy

  • Inadequate clinical data or poor sample quality

Study Design

Total Participants: 500
Treatment Group(s): 2
Primary Treatment: Small RNA sequencing
Phase:
Study Start date:
June 21, 2024
Estimated Completion Date:
June 18, 2026

Study Description

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy after hepatocellular carcinoma, accounting for approximately 10-15% of all primary liver cancers. Despite improvements in surgical techniques and imaging modalities, ICC is often diagnosed at advanced stages, resulting in dismal outcomes with a 5-year overall survival rate of 25-30%.

Traditional imaging approaches such as CT and MRI have limited sensitivity for detecting early or small ICC lesions. Blood-based biomarkers, including CA19-9, also lack adequate specificity.

Recent advances in liquid biopsy have demonstrated that exosomal microRNAs (exo-miRNAs) can serve as promising, minimally invasive biomarkers reflecting tumor biology and microenvironmental changes.

The LUMIC study (Liquid biopsy Using exosomal miRNA for Intrahepatic Cholangiocarcinoma detection) aims to identify and validate miRNA signatures capable of distinguishing ICC from benign biliary or non-cancerous liver conditions.

Blood samples are collected before treatment, and exo-miRNA expression profiles are analyzed using RT-qPCR and bioinformatic pipelines. Diagnostic performance (AUC, sensitivity, specificity) will be evaluated through training and validation cohorts.

This study provides a foundation for integrating liquid biopsy-based diagnostics into ICC clinical workflows to enable earlier detection and improved treatment stratification.

Connect with a study center

  • City of Hope Medical Center

    Duarte 5344147, California 5332921 91016
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.